Search

Your search keyword '"Bonciarelli, Giorgio"' showing total 26 results
Start Over Author "Bonciarelli, Giorgio"
26 results on '"Bonciarelli, Giorgio"'

2. GAVeCeLT* consensus statement on the correct use of totally implantable venous access devices for diagnostic radiology procedures

Author

Bonciarelli, Giorgio, Batacchi, Stefano, Biffi, Roberto, Buononato, Massimo, Damascelli, Bruno, Ghibaudo, Flavio, Orsi, Franco, Pittiruti, Mauro, Scoppettuolo, Giancarlo, Verzè, Alessia, Borasi, Guido, De Cicco, Marcello, Dosio, Roberto, Gazzo, Paolo, Maso, Renzo, Roman, Alessandro, Ticha, Vladimira, Venier, Giacomo, Blackburn, Paul, Goossens, Godelieve A., Santolucito, Jamie Bowen, Stas, Marguerite, Van Boxtel, Ton, Vesely, Thomas M., and de Lutio, Enrico

Published
2011
Full Text
View/download PDF

6. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer

Author

Dieci, Maria Vittoria, primary, Guarneri, Valentina, additional, Giarratano, Tommaso, additional, Mion, Marta, additional, Tortora, Giampaolo, additional, De Rossi, Costanza, additional, Gori, Stefania, additional, Oliani, Cristina, additional, Merlini, Laura, additional, Pasini, Felice, additional, Bonciarelli, Giorgio, additional, Griguolo, Gaia, additional, Orvieto, Enrico, additional, Michieletto, Silvia, additional, Saibene, Tania, additional, Del Bianco, Paola, additional, De Salvo, Gian Luca, additional, and Conte, PierFranco, additional

Published
2017
Full Text
View/download PDF

7. First prospective multicenter Italian study on the impact of the 21-Gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients.

Author

Dieci, Maria Vittoria, primary, Guarneri, Valentina, additional, Giarratano, Tommaso, additional, Mion, Marta, additional, Tortora, Giampaolo, additional, Morandi, Paolo, additional, Gori, Stefania, additional, Merlini, Laura, additional, Oliani, Cristina, additional, Pasini, Felice, additional, Bonciarelli, Giorgio, additional, Griguolo, Gaia, additional, Orvieto, Enrico, additional, Del Bianco, Paola, additional, De Salvo, Gian Luca, additional, and Conte, Pier Franco, additional

Published
2017
Full Text
View/download PDF

9. First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.

Author

Dieci, Maria Vittoria, Guarneri, Valentina, Giarratano, Tommaso, Mion, Marta, Tortora, Giampaolo, De Rossi, Costanza, Gori, Stefania, Oliani, Cristina, Merlini, Laura, Pasini, Felice, Bonciarelli, Giorgio, Griguolo, Gaia, Orvieto, Enrico, Michieletto, Silvia, Saibene, Tania, Del Bianco, Paola, De Salvo, Gian Luca, and Conte, PierFranco

Subjects
BREAST tumor treatment, BIOLOGICAL assay, BREAST tumors, CANCER chemotherapy, CANCER patients, CANCER relapse, COMBINED modality therapy, ESTROGEN receptors, GENE expression, HORMONE therapy, LONGITUDINAL method, MEDICAL cooperation, ONCOGENES, RESEARCH, DECISION making in clinical medicine
Abstract

Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018
Full Text
View/download PDF

10. The role of prognostic factors in metastatic renal cell carcinoma (mRCC) treated with targeted therapies (TT): Data from an Italian retrospective multicentric study.

Author

Barile, Carmen, primary, Fraccon, Anna Paola, additional, Zustovich, Fable, additional, Gaion, Fernando, additional, Salvagno, Luigi, additional, Massari, Francesco, additional, Martellucci, Ignazio, additional, Modenesi, Caterina, additional, Giusto, Mauro, additional, Segati, Romana, additional, Bearz, Alessandra, additional, Ogliosi, Chiara, additional, Macrini, Sveva, additional, Maruzzo, Marco, additional, Larussa, Francesca, additional, Nicolardi, Linda, additional, Bonciarelli, Giorgio, additional, Menon, Daniela, additional, Inno, Alessandro, additional, and Pasini, Felice, additional

Published
2013
Full Text
View/download PDF

11. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre study

Author

Grassetto, Gaia, primary, Fornasiero, Adriano, additional, Otello, Daniele, additional, Bonciarelli, Giorgio, additional, Rossi, Elena, additional, Nashimben, Ottorino, additional, Minicozzi, Anna Maria, additional, Crepaldi, Giorgio, additional, Pasini, Felice, additional, Facci, Enzo, additional, Mandoliti, Giovanni, additional, Marzola, Maria Cristina, additional, Al-Nahhas, Adil, additional, and Rubello, Domenico, additional

Published
2011
Full Text
View/download PDF

12. M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis

Author

Rossi, Elisabetta, primary, Basso, Umberto, additional, Celadin, Romina, additional, Zilio, Francesca, additional, Pucciarelli, Salvatore, additional, Aieta, Michele, additional, Barile, Carmen, additional, Sava, Teodoro, additional, Bonciarelli, Giorgio, additional, Tumolo, Salvatore, additional, Ghiotto, Cristina, additional, Magro, Cristina, additional, Jirillo, Antonio, additional, Indraccolo, Stefano, additional, Amadori, Alberto, additional, and Zamarchi, Rita, additional

Published
2010
Full Text
View/download PDF

13. Additional Value of FDG-PET/CT in Management of “Solitary” Liver Metastases: Preliminary Results of a Prospective Multicenter Study

Author

Grassetto, Gaia, primary, Fornasiero, Adriano, additional, Bonciarelli, Giorgio, additional, Banti, Elena, additional, Rampin, Lucia, additional, Marzola, Maria Cristina, additional, Massaro, Arianna, additional, Galeotti, Fabrizio, additional, Del Favero, Giuseppe, additional, Pasini, Felice, additional, Minicozzi, Anna Maria, additional, Al-Nahhas, Adil, additional, Cordiano, Claudio, additional, and Rubello, Domenico, additional

Published
2009
Full Text
View/download PDF

18. Gavecelt*Consensus Statement on the Correct use of Totally Implantable Venous Access Devices for Diagnostic Radiology Procedures

Author

Bonciarelli, Giorgio, Batacchi, Stefano, Biffi, Roberto, Buononato, Massimo, Damascelli, Bruno, Ghibaudo, Flavio, Orsi, Franco, Pittiruti, Mauro, Scoppettuolo, Giancarlo, Verzè, Alessia, Borasi, Guido, De Cicco, Marcello, Dosio, Roberto, Gazzo, Paolo, Maso, Renzo, Roman, Alessandro, Ticha, Vladimira, Venier, Giacomo, Blackburn, Paul, Goossens, Godelieve A., Santolucito, Jamie Bowen, Stas, Marguerite, Van Boxtel, Ton, Vesely, Thomas M., and de Lutio, Enrico

Abstract

The use of totally implantable venous access devices in radiology may be associated with complications such as occlusion of the system (because of the high density of some contrast), infection (if the port is not handled in aseptic conditions, using proper barrier protections), and mechanical complications due to the high-pressure administration of contrast by automatic injectors (so-called power injector), including extravasation of contrast media into the soft tissues, subintimal venous or myocardial injection, or serious damage to the device itself (breakage of the external connections, dislocation of the non-coring needle, or breakage of the catheter).The last problem – i.e., the damage of the device from a power injection – is not an unjustified fear, but a reality. A warning by the US Food and Drug Administration of July 2004 reports around 250 complications of this kind, referring to both port and central venous catheters and peripherally inserted central catheter systems, which occurred over a period of several years; in all cases, the damage occurred during the injection of contrast material by means of power injectors for computed tomography or magnetic resonance imaging procedures.Though the risk associated with the use of ports in radiodiagnostics is thus clear, it has been suggested that administration of the contrast material via the port may have some advantage in terms of image quality, increased comfort for the patient, and maybe more accurate reproducibility of the patient's own follow-up exams. This contention needs to be supported by evidence.Also, since many cancer patients who need frequent computed tomography studies already have totally implantable systems, it would seem reasonable to try to define how and when such systems may safely be used.The purpose of this consensus statement is to define recommendations based on the best available evidence, for the safe use of implantable ports in radiodiagnostics.

Published
2011
Full Text
View/download PDF

19. Pilot Study of Intravenous Administration of the Acid-Treated Salmonella Minnesota R595 (Re) in Cancer Patients

Author

Jirillo, Antonio, Disperati, Alberto, Balli, Mario, Bonciarelli, Giorgio, Demicheli, Romano, Antonaci, Salvatore, and Jirillo, Emilio

Abstract

The clinical toxicity of acetic acid-treated « Salmonella minnesota » R595 (Re) organisms was evaluated in 24 cancer patients. Bacteria were injected i.v. four times at increasing doses for a total of 6.5 μg. This therapeutic regimen was free of major side effects (one patient had fever higher than 38 °C and 10 patients complained of pruritus). Furthermore, this bacterial preparation which possesses a more exposed lipid A on its surface, exhibited immunomodulating capacities in that it normalized the inverted T helper/T suppressor ratio and enhanced natural killer activity in tumor patients. The mechanisms of the lower toxicity and immunomodulating activities of these bacteria compared to other lipid A preparations are discussed.

Published
1987
Full Text
View/download PDF

20. Pharmacologic Data and Technical Feasibility of Intraperitoneal Doxorubicin Administration

Author

Demicheli, Romano, Bonciarelli, Giorgio, Jirillo, Antonio, Foroni, Roberto, Petrosino, Luigi, Targa, Lino, and Garusi, Gianfranco

Abstract

Seventy intraperitoneal administrations of doxorubicin were performed in 12 patients with malignant disease in the abdominopelvic space. Peritoneal and hematologic drug levels were measured by fluorimetric assay. A first-order decline in the peritoneal level was determined (T1/296 ± 18 min), with a mean drug absorption of 84 % in 4 h (range 40-96 %) and a mean ratio of a peak dialysate/peak serum level of 111 (range 12-390). Gastrointestinal toxicity was common and peritoneal phlogosis occurred twice. The doxorubicin level and the time of peritoneal exposure seem to be critical factors for major local toxicity. At a moderate concentration doxorubicin can be intraperitoneally administered, but its usefullness is probably confined to patients with minimal abdominal disease.

Published
1985
Full Text
View/download PDF

21. Pharmacological Data and Technical Feasibility of Intraperitoneal 5-Fluorouracil Administration

Author

Demicheli, Romano, Jirillo, Antonio, Bonciarelli, Giorgio, Bellini, Anna, Petrosino, Luigi, Bigi, Leonardo, and Garusi, Gian Franco

Abstract

Via a surgically implanted Tenckhoff catheter, 5-fluorouracil was intraperitoneally administered to patients with malignant disease confined to abdominal space. Treatment was well tolerated without local complications. Peritoneal and plasmatic drug levels were measured, showing that: 1) peritoneal drug levels declined as a first order function; 2) plasmatic levels were very close to those reported for continuous i.v. administration, but peritoneal concentrations were much higher (log 1 to 3); 3) concentration × time product had a peritoneum: plasma ratio ranging from 120 to 1350. The hypothesized role of intraperitoneal 5-fluorouracil administration and the questions still to be answered are summarized.

Published
1982
Full Text
View/download PDF

22. Bleomycin, Vincristine, Mitomycin and Cisplatin Alternated with Cyclophosphamide, 4'-Epidoxorubicin and Procarbazine in Advanced Non-small-cell Lung Cancer

Author

Demicheli, Romano, Bonciarelli, Giorgio, Jirillo, Antonio, Lonardi, Federico, and Balli, Mario

Abstract

Thirty-eight patients with histologically confirmed non-small-cell lung cancer were treated with bleomycin, vincristin, mitomycin and cisplatin (BOMP) alternated with cyclophosphamide, 4'-epidoxorubicin and procarbazine (CEP). Twenty patients were randomized to start the treatment with BOMP and 18 with CEP. Patients underwent a median of 4 cycles (range, 1-8). The overall response rate was 36% with 2 clinical complete responses. The median duration of response was 6.5 months, the median survival time was 7.5 months, and 37% of patients survived for more than one year. The comparison between the two arms of this study and between this study and a previous investigation on the effectiveness of BOMP suggests that CEP regimen added to BOMP does not significantly improve patient outcome.

Published
1988
Full Text
View/download PDF

25. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre study

Author

Grassetto, Gaia, Fornasiero, Adriano, Otello, Daniele, Bonciarelli, Giorgio, Rossi, Elena, Nashimben, Ottorino, Minicozzi, Anna Maria, Crepaldi, Giorgio, Pasini, Felice, Facci, Enzo, Mandoliti, Giovanni, Marzola, Maria Cristina, Al-Nahhas, Adil, and Rubello, Domenico

Subjects
*BREAST cancer diagnosis, *POSITRON emission tomography, *TUMOR markers, *DIAGNOSTIC imaging, *DISEASE relapse, *BREAST cancer treatment, *FOLLOW-up studies (Medicine), *DIAGNOSIS
Abstract

Abstract: Objectives: Breast cancer is the second cause of death in women in Europe and North America. The mortality of this disease can be reduced with effective therapy and regular follow up to detect early recurrence. Tumor markers are sensitive in detecting recurrent or residual disease but imaging is required to customize the therapeutic option. Rising tumor markers and negative conventional imaging (US, X-mammography, CT and MR) poses a management problem. Our aim is to assess the role of 18F-FDG-PET/CT in the management of post-therapy patients with rising markers but negative conventional imaging. Materials and methods: In the period from January 2008 to September 2009, 89 female patients with breast cancer who developed post-therapy rising markers (serum Ca 15-3 levels=64.8±16.3U/mL) but negative clinical examination and conventional imaging were investigated with 18F-FDG-PET/CT. Results: Tumor deposits were detected in 40/89 patients in chest wall, internal mammary nodes, lungs, liver and skeleton. The mean SUVmax value calculated in these lesions was 6.6±1.7 (range 3.1–12.8). In 23/40 patients solitary small lesion were amenable to radical therapy. In 7 out of these 23 patients a complete disease remission lasting more than 1 year was observed. Conclusions: 18F-FDG-PET/CT may have a potential role in asymptomatic patients with rising markers and negative conventional imaging. Our findings agree with other studies in promoting regular investigations such as tumor markers and 18F-FDG-PET/CT rather than awaiting the developments of physical symptoms as suggested by current guidelines since the timely detection of early recurrence may have a major impact on therapy and survival. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

26. Neoadjuvant strategies for pancreatic cancer.

Author

Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, and Frego M

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, Chemoradiotherapy, Adjuvant, Chemotherapy, Adjuvant, Humans, Neoadjuvant Therapy adverse effects, Neoadjuvant Therapy mortality, Neoplasm Staging, Pancreatic Neoplasms mortality, Pancreatic Neoplasms pathology, Patient Selection, Radiotherapy, Adjuvant, Risk Factors, Time Factors, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoadjuvant Therapy methods, Pancreatectomy adverse effects, Pancreatectomy mortality, Pancreatic Neoplasms therapy
Abstract

Pancreatic cancer (PC) is the fourth cause of cancer death in Western countries, the only chance for long term survival is an R0 surgical resection that is feasible in about 10%-20% of all cases. Five years cumulative survival is less than 5% and rises to 25% for radically resected patients. About 40% has locally advanced in PC either borderline resectable (BRPC) or unresectable locally advanced (LAPC). Since LAPC and BRPC have been recognized as a particular form of PC neoadjuvant therapy (NT) has increasingly became a valid treatment option. The aim of NT is to reach local control of disease but, also, it is recognized to convert about 40% of LAPC patients to R0 resectability, thus providing a significant improvement of prognosis for responding patients. Once R0 resection is achieved, survival is comparable to that of early stage PCs treated by upfront surgery. Thus it is crucial to look for a proper patient selection. Neoadjuvant strategies are multiples and include neoadjuvant chemotherapy (nCT), and the association of nCT with radiotherapy (nCRT) given as either a combination of a radio sensitizing drug as gemcitabine or capecitabine or and concomitant irradiation or as upfront nCT followed by nRT associated to a radio sensitizing drug. This latter seem to be most promising as it may select patients who do not go on disease progression during initial treatment and seem to have a better prognosis. The clinical relevance of nCRT may be enhanced by the application of higher active protocols as FOLFIRINOX.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results